Business
TuHURA Biosciences, Inc. to Present at the 3rd Annual H.C. Wainwright BioConnect Conference
TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced that James A. Bianco, M.D., President and Chief Executive Officer of TuHURA, will present a company overview, including highlights of its IFx-Hu2.0 Phase 3 program, and its first-in-class bi-specific immune modulating Antibody drug, or peptide conjugates (ADCs, APCs) targeting Myeloid Derived Suppressor Cells (MDSCs), a
About this update from Tuhura Biosciences, Inc.
[{"type":"text","content":"TAMPA, Fla., May 13, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced that James A. Bianco, M.D., President and Chief Executive Officer of TuHURA, will present a company overview, including highlights of its IFx-Hu2.0 Phase 3 program, and its first-in-class bi-specific immune modulating Antibody drug, or peptide conjugates (ADCs, APCs) targeting Myeloid Derived Suppressor Cells (MDSCs), along with Kineta Inc's. VISTA inhibiting monoclonal antibody program, at the 3rd Annual H.C. Wainwright BioConnect Investor Conference at NASDAQ on Tuesday, May 20, 2025, at 2:30 PM ET.","length":746,"tagName":"p"},{"type":"text","content":"In addition to the presentation, management will be available to participate in one-on-one in-person meetings with qualified members of the investor community who are registered to attend the conference. For more information about the event, please visit the conference website.","length":278,"tagName":"p","attribs":{}},{"type":"text","content":"A live webcast of the fireside chat will be available on the Events page of the Investors section of the Company's website (tuhurabio.com), and is also accessible here.","length":172,"tagName":"p","attribs":{}},{"type":"text","content":"As previously announced, on December 11, 2024, TuHURA entered into a definitive agreement with Kineta, Inc. (OTC Pink: KANT) ("Kineta") in which, as amended, TuHURA agreed to acquire Kineta, including the rights to Kineta's novel KVA12123 antibody, for a combination of cash and shares of TuHURA common stock via a merger transaction upon the terms and conditions described in TuHURA's Forms 8-K filed on December 12, 2024 and May 7, 2025. The merger is currently targeted to close in Q2 2025 pending the satisfaction of certain closing conditions.","length":566,"tagName":"p","attribs":{}},{"type":"text","content":"About TuHURA Biosciences, Inc.","length":30,"tagName":"p","attribs":{}},{"type":"text","content":"TuHURA Biosciences, Inc. (Nasdaq: HURA) is a Phase 3 immuno-oncology company developing novel technologies to overcome primary and acquired resistance to cancer immunotherapy, two of the most common reasons cancer immunotherapies fail to work or s...